Feature | May 15, 2012| Dave Fornell

Trends and Advances in Cardiac SPECT and SPECT/CT

Myocardial perfusion study performed on a Philips Precedence SPECT/CT system showing ischemia.

Single photon emission computed tomography (SPECT) remains a well-entrenched imaging modality for nuclear myocardial perfusion imaging (MPI) more than 30 years after its introduction. Due to SPECT’s reliability, cost-effectiveness and the wealth of data showing its clinical validation, it remains more common in MPI than its competition, positron emission tomography (PET). This is despite data showing PET’s much shorter scan times, fewer artifacts and better accuracy. 

The high cost of the only FDA-approved, generator-based PET MPI agent, CardioGen-82, is a key factor keeping SPECT as the dominant modality. Cardiac PET took a further blow this past year when CardioGen-82 was abruptly pulled off the U.S. market in July 2011, after two patients set off radiation detectors at U.S. border crossings due to strontium breakthroughs. The agent uses a strontium (Sr)-82 generator to produce a rubidium (Rb)-82 radiotracer injection, but it requires close daily monitoring to prevent breakthroughs. The manufacturer, Bracco, is working with the FDA to bring the radiotracer back to market.

While SPECT technology has remained somewhat stagnant over the years, recent advances have improved the speed of exams and the diagnostic accuracy of the modality. 

New gamma camera technology has allowed imaging times to be reduced from about 15-20 minutes down to about two to four minutes. Advances include both new camera design for better photon acquisition and sensitivity and better image reconstruction software.[1] 

Wide beam reconstruction (WBR), a software program from UltraSPECT, reduces both dose and image acquisition time by 50 percent for SPECT MPI.[2] Researchers found that with either half the dose of Tc-99m sestamibi or half the acquisition time, WBR resulted in image quality superior to processing with today’s widely used OSEM (ordered subset expectation maximization) software. WBR’s reconstruction algorithm incorporates depth-dependent resolution recovery and image noise modeling to deliver a higher quality image with lower count density data. 

Newer Systems

The adoption of combined SPECT/CT in one imaging system using a single patient table is growing. The combination of CT (computed tomography) offers anatomical imaging in addition to the functional molecular imaging of SPECT. In addition, CT is used for attenuation correction, resulting in better SPECT image quality and reduction in attenuation artifacts, especially in obese patients. 

A major trend is the development of new dedicated cameras/detectors for cardiac-specific imaging. Spectrum Dynamics D-SPECT last year introduced a new-generation cadmium zinc telluride (CZT) detector that enables high-resolution, low-dose nuclear scans.

Frost & Sullivan recently recognized Siemens with the 2011 North America Product Differentiation Excellence of the Year Award for its IQ-SPECT system. It offers high-quality imaging by achieving maximum counts in one-fourth the amount of time required by conventional SPECT systems. The system features special collimators to focus on the heart, collecting up to four times more counts than conventional, parallel-hole collimators. A 3-D reconstruction algorithm models the position of each of the 48,000 collimator holes on each detector. This enables sophisticated distant-dependent isotropic (3-D) resolution recovery. It can complete a full SPECT scan in as little as four minutes. 

GE Healthcare received U.S. clearance for the Brivo NM615 in January. The advanced single-head gamma camera enables lower amounts (up to 50 percent) of radiotracers and the potential for shorter exam times. This is made possible with a new detector design. The system is designed to handle larger patients with a 70 cm bore and table capable of handling patients up to 500 pounds. The system can be upgraded easily onsite to the Discovery NM630 or the Discovery NM/CT 670 SPECT/CT hybrid systems.  

Comparison Chart

This story was an introduction to the SPECT and SPECT/CT comparison cahrt that appeared in the May-June 2012 issue of DAIC. To access the chart, click on the "Comparison Chart" tab at the top of the website page. Participants in the chart include:


Digirad - www.digirad.com

GE Healthcare - www.gehealthcare.com

Philips Healthcare - www.healthcare.philips.com

Siemens Medical Solutions - www.medical.siemens.com


1. Tali Sharir, Piotr J. Slomka, Sean W. Hayes, et al. “Multicenter Trial of High-Speed Versus Conventional Single-Photon Emission Computed Tomography Imaging: Quantitative Results of Myocardial Perfusion and Left Ventricular Function.” JACC, May 4, 2010, Vol. 55, No. 18.
2. E. Gordon DePuey MD, Srinivas Bommireddipalli MD, John Clark CNMT, “A comparison of the image quality of full-time myocardial perfusion SPECT vs wide beam reconstruction half-time and half-dose SPECT.” Journal of Nuclear Cardiolog, April 2011, Vol. 18, No. 2. 

Related Content

GE Healthcare, molecular imaging, PET/CT, Discovery IQ, Discovery NM/CT 670 Pro, RSNA 2015

Discovery IQ PET/CT scanner image courtesy of GE Healthcare

News | Nuclear Imaging| November 16, 2015
GE Healthcare’s Molecular Imaging business will showcase the Discovery IQ positron emission tomography/computed...
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging| September 23, 2015
September 23, 2015 — New research de
Novation, Mo-99, NNSA 2015 meeting, reliable supplies, domestic production
News | Radiopharmaceuticals and Tracers| September 17, 2015
At the National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, Novation offered its support of...
PET, imaging agent, hidden blood clots, MGH, radiopharmaceutical probe, 64Cu-FBP8
News | Radiopharmaceuticals and Tracers| September 16, 2015
A novel radiopharmaceutical probe developed at Massachusetts General Hospital (MGH) has the potential of providing...
Zevacor, IBA, 70 MeV cyclotron, Cyclone 70P, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers| September 11, 2015
Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon...
News | Radiopharmaceuticals and Tracers| September 11, 2015
Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore...
NorthStar Medical Radioisotopes, approval, routine production, Molybdenum-99, Mo-99, University of Missouri Research Reactor, MURR
News | Radiopharmaceuticals and Tracers| August 31, 2015
NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the...
Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard
News | Radiopharmaceuticals and Tracers| July 30, 2015
Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept...
Medraysintell, nuclear medicine, World Market Report, radiopharmaceuticals
News | Nuclear Imaging| July 06, 2015
Medraysintell released its updated World Market Report and Directory on Nuclear Medicine, Edition 2015, in late June,...
nuclear medicine diagnostic market, North America, PET, SPECT, Mordor
News | Nuclear Imaging| June 29, 2015
The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for...
Overlay Init